ARTV (Artiva Biotherapeutics) Total Equity: $87.85 Mil (As of Mar. 2026)


ARTV Artiva Biotherapeutics Inc ARTV
12 GF Score
Price $9.81
! 3 Warning Signs
View Full Analysis

What is Artiva Biotherapeutics Total Equity?

Artiva Biotherapeutics ARTV +1.03% 12 Total Equity is $87.85 Mil as of Mar. 2026. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Artiva Biotherapeutics's total equity for the quarter that ended in Mar. 2026 was $87.85 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Artiva Biotherapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Artiva Biotherapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artiva Biotherapeutics Total Equity Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial -88.86 -140.70 -162.02 186.64 109.97

Artiva Biotherapeutics Quarterly Data
Dec19 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.78 149.04 129.22 109.97 87.85
ARTV
12GF Score
Artiva Biotherapeutics Inc ARTV
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artiva Biotherapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Artiva Biotherapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=130.94-20.97
=109.97

Artiva Biotherapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=105.955-18.108
=87.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $87.85 Mil mean?
Artiva Biotherapeutics (ARTV) has a Total Equity of $87.85 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Artiva Biotherapeutics and its competitors.
Is Artiva Biotherapeutics' Total Equity too high?
Artiva Biotherapeutics' current Total Equity is $87.85 Mil. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' Total Equity compare to OVID and INDP?
Artiva Biotherapeutics' Total Equity of $87.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Artiva Biotherapeutics and its competitors. Artiva Biotherapeutics's current Total Equity is $87.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current Total Equity of $87.85 Mil. The current Total Equity is $87.85 Mil. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current Total Equity is $87.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artiva Biotherapeutics Business Description

Address 5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score

Get the complete analysis for ARTV

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.81
Price